C-Path and FARA announce collaborative data aggregation project for Friedreich’s ataxia Tucson, AZ, and Downingtown, PA — December 4, 2017 — Critical Path Institute‘s (C-Path) Data Colla
January 12, 2017 A Standardised Method for Interpreting the Association Between Mutations and Phenotypic Drug Resistance in Mycobacterium Tuberculosis
January 12, 2017 Emerging Good Practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) Measures
January 12, 2017 Patient-Reported Outcome (PRO) Consortium Translation Process: Consensus Development of Updated Best Practices
November 25, 2017 Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development
FDA CDER Regulatory Science: The Importance of Partnership and Consortia Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research within the United States Food and Drug Administration,
April 11, 2017 Allowing Respondents to Skip Items During Electronic Collection of Patient-Reported Outcome (PRO) Data: Does It Matter?
April 11, 2017 Evaluating the Conceptual Equivalence Between Paper and Three Electronic Data Collection Modes of the EQ-5D-5L Health Status Instrument